Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer

Kavitha Ramachandran, Carl Speer, Lubov Nathanson, Martha Claros, Rakesh Singal

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

BACKGROUND/AIM: Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. However, the median time to progression on cabazitaxel is 2.8 months. We aimed to determine whether DNA methylation plays a role in cabazitaxel resistance.

MATERIALS AND METHODS: DU145 cells, resistant to docetaxel and cabaxitaxel (DU145 10DRCR), were generated from cells resistant to 10 nM docetaxel (DU145 10DR). The effect of pre-treatment with 5-azacytidine was determined with regards to cabazitaxel sensitivity. Gene expression profiling was carried-out on DU145 10DR, DU145 10DRCR and DU145 10DRCR treated with 5-azacytidine.

RESULTS: Pre-treatment of cells with 5-azacytidine resulted in enhanced sensitivity to cabazitaxel. Gene expression profiling identified a subset of genes that may be regulated by DNA methylation.

CONCLUSION: Our results indicate that DNA methylation of pro-apoptotic and cell-cycle regulatory genes may contribute to cabazitaxel resistance and pre-treatment with 5-azacytidine may restore sensitivity to cabazitaxel in prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)161-168
Number of pages8
JournalAnticancer Research
Volume36
Issue number1
StatePublished - Jan 1 2016

Fingerprint

DNA Methylation
docetaxel
Prostatic Neoplasms
Azacitidine
Gene Expression Profiling
cdc Genes
Castration
Regulator Genes
cabazitaxel
Genes

Keywords

  • DNA methylation
  • drug resistance
  • Epigenetics
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ramachandran, K., Speer, C., Nathanson, L., Claros, M., & Singal, R. (2016). Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer. Anticancer Research, 36(1), 161-168.

Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer. / Ramachandran, Kavitha; Speer, Carl; Nathanson, Lubov; Claros, Martha; Singal, Rakesh.

In: Anticancer Research, Vol. 36, No. 1, 01.01.2016, p. 161-168.

Research output: Contribution to journalArticle

Ramachandran, K, Speer, C, Nathanson, L, Claros, M & Singal, R 2016, 'Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer', Anticancer Research, vol. 36, no. 1, pp. 161-168.
Ramachandran K, Speer C, Nathanson L, Claros M, Singal R. Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer. Anticancer Research. 2016 Jan 1;36(1):161-168.
Ramachandran, Kavitha ; Speer, Carl ; Nathanson, Lubov ; Claros, Martha ; Singal, Rakesh. / Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer. In: Anticancer Research. 2016 ; Vol. 36, No. 1. pp. 161-168.
@article{4f9119f8e4c6403d995af8eec650673d,
title = "Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer",
abstract = "BACKGROUND/AIM: Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. However, the median time to progression on cabazitaxel is 2.8 months. We aimed to determine whether DNA methylation plays a role in cabazitaxel resistance.MATERIALS AND METHODS: DU145 cells, resistant to docetaxel and cabaxitaxel (DU145 10DRCR), were generated from cells resistant to 10 nM docetaxel (DU145 10DR). The effect of pre-treatment with 5-azacytidine was determined with regards to cabazitaxel sensitivity. Gene expression profiling was carried-out on DU145 10DR, DU145 10DRCR and DU145 10DRCR treated with 5-azacytidine.RESULTS: Pre-treatment of cells with 5-azacytidine resulted in enhanced sensitivity to cabazitaxel. Gene expression profiling identified a subset of genes that may be regulated by DNA methylation.CONCLUSION: Our results indicate that DNA methylation of pro-apoptotic and cell-cycle regulatory genes may contribute to cabazitaxel resistance and pre-treatment with 5-azacytidine may restore sensitivity to cabazitaxel in prostate cancer cells.",
keywords = "DNA methylation, drug resistance, Epigenetics, prostate cancer",
author = "Kavitha Ramachandran and Carl Speer and Lubov Nathanson and Martha Claros and Rakesh Singal",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "36",
pages = "161--168",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer

AU - Ramachandran, Kavitha

AU - Speer, Carl

AU - Nathanson, Lubov

AU - Claros, Martha

AU - Singal, Rakesh

PY - 2016/1/1

Y1 - 2016/1/1

N2 - BACKGROUND/AIM: Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. However, the median time to progression on cabazitaxel is 2.8 months. We aimed to determine whether DNA methylation plays a role in cabazitaxel resistance.MATERIALS AND METHODS: DU145 cells, resistant to docetaxel and cabaxitaxel (DU145 10DRCR), were generated from cells resistant to 10 nM docetaxel (DU145 10DR). The effect of pre-treatment with 5-azacytidine was determined with regards to cabazitaxel sensitivity. Gene expression profiling was carried-out on DU145 10DR, DU145 10DRCR and DU145 10DRCR treated with 5-azacytidine.RESULTS: Pre-treatment of cells with 5-azacytidine resulted in enhanced sensitivity to cabazitaxel. Gene expression profiling identified a subset of genes that may be regulated by DNA methylation.CONCLUSION: Our results indicate that DNA methylation of pro-apoptotic and cell-cycle regulatory genes may contribute to cabazitaxel resistance and pre-treatment with 5-azacytidine may restore sensitivity to cabazitaxel in prostate cancer cells.

AB - BACKGROUND/AIM: Cabazitaxel is an approved second-line treatment for docetaxel-refractory metastatic castration-resistant prostate cancer. However, the median time to progression on cabazitaxel is 2.8 months. We aimed to determine whether DNA methylation plays a role in cabazitaxel resistance.MATERIALS AND METHODS: DU145 cells, resistant to docetaxel and cabaxitaxel (DU145 10DRCR), were generated from cells resistant to 10 nM docetaxel (DU145 10DR). The effect of pre-treatment with 5-azacytidine was determined with regards to cabazitaxel sensitivity. Gene expression profiling was carried-out on DU145 10DR, DU145 10DRCR and DU145 10DRCR treated with 5-azacytidine.RESULTS: Pre-treatment of cells with 5-azacytidine resulted in enhanced sensitivity to cabazitaxel. Gene expression profiling identified a subset of genes that may be regulated by DNA methylation.CONCLUSION: Our results indicate that DNA methylation of pro-apoptotic and cell-cycle regulatory genes may contribute to cabazitaxel resistance and pre-treatment with 5-azacytidine may restore sensitivity to cabazitaxel in prostate cancer cells.

KW - DNA methylation

KW - drug resistance

KW - Epigenetics

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85003046899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003046899&partnerID=8YFLogxK

M3 - Article

C2 - 26722040

AN - SCOPUS:85003046899

VL - 36

SP - 161

EP - 168

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -